BASF Builds New Plant in Germany
PTSM: Pharmaceutical Technology Sourcing and Management
BASF builds a new plant for specialty amines in Ludwigshafen, Germany.
BASF
is building a new plant for the production of specialty amines in Ludwigshafen, Germany. The facility, with a total annual capacity of about 12,000 metric tons, is scheduled for completion in 2015. The product range of this multi-product plant comprises 15 amines for different applications. With this new facility, BASF continues to expand its network of amines with plants in Ludwigshafen and Schwarzheide in Germany; Antwerp, Belgium; Geismar, Louisiana; and Nanjing, China.
In addition, BASF announced in March that it is building another new multi-product plant for the production of specialty amines at the BASF Verbund site in Nanjing, China. The main products of this plant will be dimethylaminopropylamine (DMAPA) and polyetheramine (PEA). This facility is also expected to be complete in 2015.
Source:
BASF
How Smart Technology is Helping Reach Sustainability Goals in Drug Packaging
June 7th 2025Smart technologies, such as digital and laser printing, incorporated into manufacturing equipment are helping manufacturers align with sustainability goals, according to Sheikh Akbar Ali, general manager and head of Development and Technology for ACG Packaging Materials.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
